Adoptive cell therapy using TILs shows clinically meaningful and durable efficacy in advanced mucosal melanoma
Antitumour responses were consistent with those previously reported for a broader population of patients with advanced melanoma
TIL therapy – an opportunity for a few centres?
Regulatory, practical and economic challenges are associated with implementing this personalised treatment on a larger scale, thus currently limiting its availability and accessibility to patients
TILs confirm to prolong PFS compared with immunotherapy in advanced melanoma
In a head-to-head comparison to the standard of care, tumour-infiltrating lymphocytes show clinical efficacy even in patients who are refractory to anti-PD-1 treatment
How to integrate tebentafusp in the checkpoint-based clinical management of patients with uveal melanoma?
Since its approval, tebentafusp is changing the treatment landscape for patients with metastatic uveal melanoma, but many questions remain
AI and machine learning may change the course of translational research
However, according to the winner of the ESMO Award for Translational Research 2022, Dr Samra Turajlic, results will only be achieved through a collaborative effort of the oncology community
Immunotherapy confirmed as standard of care for melanoma brain metastases
Studies also suggest hope for TKI inhibitor combinations in patients with symptomatic brain metastases
A step closer to determining the best sequential approach for treatment of BRAF-mutated metastatic melanoma?
Data from SECOMBIT provide useful insights to the optimal sequence of immune checkpoint inhibitor therapy and targeted treatment combinations for patients with BRAF-mutated, advanced melanoma
Adjuvant pembrolizumab prolongs relapse-free survival in resected stage II melanoma
Immunotherapy was associated with a significant reduction in the risk of disease recurrence compared with placebo in patients with melanoma
The role of T-VEC in the treatment of advanced melanoma: just a matter of combinations?
The oncolytic herpes virotherapy does not show survival benefit in combination with pembrolizumab, but encouraging early data are reported with intratumoural injection of myeloid dendritic cells